BioNTech Buys German Site To Ramp Up Covid-19 Vaccine Production
Muhammad Irfan Published September 17, 2020 | 06:39 PM
Germany's BioNTech, one of the lead contenders in the race to develop a coronavirus vaccine, said Thursday it was buying a new manufacturing site to quickly ramp up production once its vaccine gets the green light
Frankfurt am Main, (APP - UrduPoint / Pakistan Point News - 17th Sep, 2020 ) :Germany's BioNTech, one of the lead contenders in the race to develop a coronavirus vaccine, said Thursday it was buying a new manufacturing site to quickly ramp up production once its vaccine gets the green light.
The firm said it had agree to acquire a "state-of-the-art" production facility in the western German city of Marburg from Swiss pharma giant Novartis.
"This acquisition reflects BioNTech's commitment to significantly expanding its manufacturing capacity in order to supply a potential vaccine worldwide upon authorisation or approval," finance chief Sierk Poetting said in a statement.
The Marburg site will scale up BioNTech's Covid-19 vaccine production capacity by up to 750 million additional doses per year, or over 60 million doses per month, "once fully operational", the statement added.
No financial details were revealed.
The deal is expected to close in the fourth quarter of 2020, and the 300 Novartis staff at the site will switch to working for BioNTech.
Mainz-based BioNTech is teaming up with US behemoth Pfizer to develop a coronavirus vaccine using new technology based on mRNA, a type of genetic material never before used to make a vaccine.
They already have one vaccine candidate in the late-stage Phase 3 trial that is currently being tested on around 30,000 volunteers.
Just eight other vaccine candidates globally have reached this stage so far.
The European Union, the United States and several other countries have already announced large contracts to secure millions of doses of the possible BioNTech-Pfizer vaccine once it clears all the necessary regulatory hurdles.
Ahead of the Marburg acquisition, BioNTech said it planned to supply up to 100 million doses by the end of 2020 if its vaccine is successful, and 1.3 billion doses by the end of 2021.
Next year's number is now expected to be "significantly" higher, a spokeswoman told AFP.
The Marburg purchase comes just days after BioNTech received a 375-million-euro ($440-million) funding boost from the German government.
Related Topics
Recent Stories
3 Gawadar attack victims funeral offered
Mbappe says he will leave PSG at end of season
Usmani felicitates Sardar Saleem on taking oath as Punjab Governor
DC for provision of facilities to people in Lasbela
Solar storm could bring auroras, power and telecoms disruptions
Court grants interim bail to PTI leaders
Ulema, Mashaykh call for political accountability, collaboration for Pakistan's ..
SHRC asks NADRA to issue CNICs to transgender as per law
Flash floods kill 50 in one day in north Afghanistan
CDA chief expresses commitment to promoting modern-day technologies
By wide margin, UN General Assembly votes to back Palestinian bid for membership ..
Musadik slams PTI's political approach as provocative
More Stories From World
-
Endrick in Brazil's Copa America squad but no Neymar
6 hours ago -
Djokovic bottle strike overshadows Rome Open cruise past Moutet
6 hours ago -
Train crash in Argentine capital leaves 30 injured
6 hours ago -
Pandemic agreement talks to continue beyond deadline
6 hours ago -
Chopra falls short in Doha, Bednarek blitzes before Olympics
6 hours ago -
Djokovic struck with bottle from stands after winning Rome opener
6 hours ago
-
England great Anderson's Test career under threat after McCullum talks - report
7 hours ago -
Senegal launches inquiry into Boeing jet runway crash
7 hours ago -
Madagascan leader's former aide jailed in UK for graft
7 hours ago -
Seven killed as bus crashes into river in Russia's St Petersburg
8 hours ago -
Mbappe confirms he will leave PSG at end of season
8 hours ago -
Fresh rains pound Brazil's flood-hit south as evacuations double
8 hours ago